|
Key Value Drivers
Technology: Bonenta has exclusive license to a
platform technology, patented November, 2006, with great potential for
discovery of new drugs for bone healing.
Competitive Advantage: Broad patent portfolio (expire 2027) * B247 is patent protected * in-house R&D capabilities * $2.2 MM in NIH validation funding * skilled, scientific and management personnel team * compelling competing efficacy data.
Plan & Strategy: Bonenta was formed as a Delaware C-corporation for the purpose of advancing this bone graft technology. We currently await longer-term pre-clinical B247 results for 6 and 12 week graft periods to more fully evaluate the product’s competitive advantage in this important market, and these will be completed by January 2011.
Establishing strategic corporate
partnership(s) with current industry leaders while welcoming the strength and
advantages of private financing will help us best commercialize our lead
product and our pipeline candidates.
|
|
|